VERONA PHARMA PLC - AM

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

15 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

10 Aug 2022 19:22:20 By Nasdaq GlobeNewswire

Verona Pharma plc Announces Proposed Underwritten Public Offering

09 Aug 2022 15:16:44 By Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update

09 Aug 2022 02:01:03 By Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD

09 Aug 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD

08 Aug 2022 15:30:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

29 Jul 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

09 Jun 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Host KOL Event on June 16, 2022

06 Jun 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies Healthcare Conference

25 May 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022

09 May 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces May 2022 Investor Conference Participation

04 May 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update

03 May 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update

19 Apr 2022 01:00:00 By Nasdaq GlobeNewswire

James Brady Joins Verona Pharma as Non-Executive Director

14 Mar 2022 02:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

03 Mar 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

17 Feb 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

24 Jan 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

05 Jan 2022 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

04 Jan 2022 01:00:00 By Nasdaq GlobeNewswire